HALOPERIDOL LACTATE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C21H23ClFNO2.C3H6O3
Molecular Weight	465.942
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Cl)C=C3

InChI

InChIKey=BVUSNQJCSYDJJG-UHFFFAOYSA-N

InChI=1S/C21H23ClFNO2.C3H6O3/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16;1-2(4)3(5)6/h3-10,26H,1-2,11-15H2;2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula	C21H23ClFNO2
Molecular Weight	375.864
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00502
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D4 receptor 76 Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14611858	Inverse Agonist 85	17.0 nM [EC50]
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00502	Antagonist 2849
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7520908	Antagonist 2849	53.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 305 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 8583	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 1986
Tourette's syndrome 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf	Primary		Approved 8583	HALDOL Approved Use HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder. Launch Date 1986

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	substrate 1388 activator 25 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2J2 33 P-gp 1741 OCT1 620 BCRP 910 MRP2 499 MDR3 8 Kv4.3 16 CYP1A2 2153 CYP2A6 879 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 BSEP 550 MRP3 246 MRP4 290 OATP1B1 1079 OATP1B3 961	CYP1A2 1197 CYP1A1 389 CYP2C8 810 CYP2C19 1119 CYP3A5 446 UGT 219 UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A6 343 UGT1A9 423 UGT2B7 456 UGT2B15 236 P-gp 2052 OCT1 393 MATE1 182

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3 \| https://pubmed.ncbi.nlm.nih.gov/10460810/	moderate [Ki 7.2 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	no [IC50 >10 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://pubmed.ncbi.nlm.nih.gov/18457386/	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	no [IC50 >30 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://pubmed.ncbi.nlm.nih.gov/23033255/	no [IC50 >50 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19421845/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU0In19	yes [Activation 31.6228 uM]
MDR3 9	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/26335978/	yes [IC50 10.7 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/	yes [IC50 141.9 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 2.87 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891329/, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 25.3 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16810505/	yes [IC50 25.4 uM]
Kv4.3 16	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24998874/	yes [IC50 3.6 uM]
CYP2J2 36	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23033255/	yes [IC50 4.69 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9431831/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3336800/	yes [IC50 8.2 uM]
CYP2D6 2546	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/9681669/, https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000052868	yes
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12031686/	likely [Km 33 uM]
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=8 Page: (Label) 8, 27	major
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	major
CYP2D6 1388	substrate 4014 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of CYP2D6 inhibitors (chlorpromazine, promethazine, quinidine, paroxetine, sertraline, venlafaxine) increased Haloperidol plasma concentrations. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP3A4 1946	substrate 4014 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28	major	yes (co-administration study) Comment: Coadministration of Rifampicin (strong CYP3A4 inducer) decreased plasma Haloperidol levels by a mean of 70%. Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null Page: (Label) 9, 28
CYP1A2 1197	substrate 4014 Sources: https://link.springer.com/article/10.1007/s40262-016-0407-2/tables/3, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C537&ns=ncit&type=relationship&key=113214754&b=1&n=0&vse=null	minor
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	minor
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/32294459/	no
CYP1A1 389	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11717183/	yes
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/31842924/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/18448342/, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf#page=9, https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1038/sj.bjp.0705025 Page: (Label) 9, 28

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5613	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5613
ChemicalBook	CB32131152	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32131152
ChemicalBook	CB72509133	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72509133
ChemicalBook	CB7774829	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7774829
eMolecules	538987	https://www.emolecules.com/cgi-bin/more?vid=538987
MolPort	MolPort-000-883-311	https://www.molport.com/shop/molecule-link/MolPort-000-883-311
Selleck Chemicals	Haloperidol(Haldol)	http://www.selleckchem.com/products/Haloperidol(Haldol).html
ZINC	ZINC000000537822	http://zinc15.docking.org/substances/ZINC000000537822

PubMed

Title	Date	PubMed
Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat.	1976 Jul	1033561
Effect of angiotensin on the central action of dopamine.	1976 Nov-Dec	1034924
Parkinsonism by haloperidol and piribedil.	1978 Oct 31	103114
Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy.	1979 Mar 29	108749
Behavioral changes as a result of dotarizine or flunarizine influence on dopaminergic neurotransmission in the striatum.	1998	10347616
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?	1999	10651103
Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors.	1999	10613497
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.	1999 Apr	10353425
Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRgamma1 isoform.	1999 Apr	10336693
Sexual disturbances during clozapine and haloperidol treatment for schizophrenia.	1999 Apr	10200746
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.	1999 Dec	10628507
Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice.	1999 Feb	10368871
Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.	1999 Jul	10379522
Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation.	1999 Jun	10435392
Interaction between olanzapine and haloperidol.	1999 Jun	10350035
The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice.	1999 Mar	10227083
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report.	1999 May	10362445
Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.	1999 Nov	10669905
The effects of benzamide analogues on cocaine self-administration in rhesus monkeys.	1999 Nov	10591881
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.	1999 Nov	10591873
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.	1999 Nov 26	10594343
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.	1999 Oct	10589449
Haloperidol-induced torsade de pointes.	1999 Oct	10534216
Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.	1999 Oct 8	10528146
Two additional uses for sildenafil in psychiatric patients.	1999 Oct-Dec	10546163
A case of leukocytoclastic vasculitis associated with haloperidol.	1999 Sep	10564343
Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.	1999 Sep	10495006
Risperidone in treatment-refractory schizophrenia.	1999 Sep	10484947
The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity.	2000	11026478
Effect of muscarinic receptor agonists on animal models of psychosis.	2000 Apr	10893700
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.	2000 Apr	10780978
Prolonged upper airway instability in the parenteral use of benzodiazepine with levomepromazine.	2000 Feb	10653217
Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.	2000 Jan	10672628
Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration.	2000 Jan 21	10670778
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.	2000 Jan 3	10661492
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.	2000 Jul	10871703
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.	2000 Jul	10869885
Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential.	2000 Jun	10875735
Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment.	2000 Mar	10928308
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.	2000 Mar	10744342
Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery.	2000 Mar	10730737
Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.	2000 Mar	10693159
No changes in dopamine D(1) receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration.	2000 Mar 24	10719094
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.	2000 May	10888308
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.	2000 May	10868556
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.	2000 May	10847307
Haloperidol-induced catalepsy is influenced by calcium channel antagonists.	2000 May-Jun	11143713
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.	2000 Nov	11100936
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.	2000 Nov	11071396
Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain.	2000 Oct	10987852

Patents

Sample Use Guides

In Vivo Use Guide

Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.

Route of Administration: Intramuscular

In Vitro Use Guide

10 uM Haloperidol induced a 54% decrease in the mRNA expression of ABCA1 in murineperitoneal macrophages.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:58 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:58 GMT 2025`
Record UNII	6387S86PK3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HALOPERIDOL LACTATE

Common Name

English

HALOPERIDOL INTENSOL

Preferred Name

English

(±)-HALOPERIDOL LACTATE

Common Name

English

HALOPERIDOL LACTATE [VANDF]

Common Name

English

Haloperidol lactate [WHO-DD]

Common Name

English

HALOPERIDOL LACTATE, (±)-

Common Name

English

PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-1-BUTANONE (1:1)

Common Name

English

1-BUTANONE, 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-, 2-HYDROXYPROPANOATE (SALT)

Common Name

English

HALOPERIDOL LACTATE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883